换一批Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
第一作者：
Owen A,O'Connor
第一单位：
Lymphoid Development and Malignancy Program, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032, USA. oo2130@columbia.edu
作者：
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);氨基蝶呤(Aminopterin);便秘(Constipation);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);抗药性, 肿瘤(Drug Resistance, Neoplasm);疲劳(Fatigue);女(雌)性(Female);叶酸拮抗剂(Folic Acid Antagonists);人类(Humans);淋巴瘤, T细胞(Lymphoma, T-Cell);男(雄)性(Male);中年人(Middle Aged);复发(Recurrence);缓解诱导(Remission Induction);口炎(Stomatitis);治疗结果(Treatment Outcome);体重减轻(Weight Loss);青年人(Young Adult)
DOI
10.1200/JCO.2008.20.8470
PMID
19652067
发布时间
2022-04-09
- 浏览10
Journal of clinical oncology
4357-64页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
